# rs56007086 and Breast cancer (16q12)

Configuration `no_qbic`, named mode, seed 0. Models: generator deepseek/deepseek-v4.1-flash-1017, critic deepseek/deepseek-v4.1-flash-1017, summariser deepseek/deepseek-v4.1-flash-1017. Cost $0.02 over 9 model calls; 280 s.

Variant `chr16:52565398:G>A` (germline); expression context: DepMap:ACH-000019 (MCF7).

## Ranked chains

### 1. C4_null_no_TF_effect_linked_or_passenger: No TF-mediated effect of rs56007086 itself (p = 0.60)

Null chain: no TF-mediated effect of this variant.

Predictions: rs56007086 shows no reproducible allele-specific TF binding in a direct assay, even though FOXA1 may occupy the broader region in MCF7.; Editing rs56007086 alone does not change TOX3 expression or breast-cancer-relevant enhancer activity.; The 16q12 breast cancer signal at this locus is better explained by a linked causal variant such as rs4784227, or by no functional effect of rs56007086; the variant has no GWAS Catalog, Open Targets, GTEx breast eQTL, or variant-specific literature support.

Falsified if: A direct allele-specific binding assay shows a reproducible TF preference for one rs56007086 allele.; CRISPR editing of rs56007086 alone changes TOX3 expression or a breast cancer phenotype in a relevant cell type.; Fine-mapping or functional dissection shows rs56007086 is the functional variant independent of other TOX3-locus variants.

### 2. C1_FOXA1_alt_enhancer_TOX3: Alt allele strengthens FOXA1 binding at a TOX3 enhancer (p = 0.30)

TF FOXA1 (stated coverage not_checked; registry own_model), alt allele binds more; element ENSR16_9QTBS / nearby dELS EH38E3180851; gene TOX3; cell type MCF7 breast cancer.

| Step | Claim | Status | Evidence |
| --- | --- | --- | --- |
| binding | FOXA1 occupies the rs56007086 region in MCF7: an ENCODE FOXA1 ChIP-seq peak in MCF-7 contains chr16:52565398:G>A. This supports FOXA1 occupancy at the locus but not allele-specific binding; the claim that the alt A allele binds FOXA1 more strongly than ref G is a hypothesis, not demonstrated by the supplied evidence. FOXA1 QBiC-SELEX coverage is not_checked. | weak | [E07](#e07) |
| element | The variant is annotated within the ENSR16_9QTBS enhancer, and a dELS EH38E3180851 with DNase and H3K27ac signal lies 38 bp away. E03 states that no cCRE overlaps the variant and gives biosample-maximal, not MCF7-specific, signal, so the element assignment is candidate-level. | supported | [E01](#e01), [E03](#e03) |
| gene | TOX3 is the nearest protein-coding gene, 17.6 kb upstream, and CASC16 overlaps the variant. This is proximity evidence only; there is no significant breast-tissue eQTL for this variant in GTEx v8. | weak | [E01](#e01), [E02](#e02), [E08](#e08) |
| cell_type | MCF7 is the supplied expression context, and E07 shows a FOXA1 ChIP-seq peak containing the variant in MCF-7, supporting FOXA1 occupancy at this locus in this cell type. Allele-specific occupancy in MCF7 is still untested. | supported | [E07](#e07) |
| phenotype | TOX3 is a breast cancer candidate locus and a known TOX3 enhancer variant, rs4784227, has been linked to breast cancer. There is no variant-specific GWAS, Open Targets or literature record for rs56007086, so disease relevance is inherited from TOX3 and is indirect. | weak | [E06a](#e06a), [E06b](#e06b), [E04](#e04), [E05](#e05), [E09](#e09) |

Predictions: An allele-specific FOXA1 assay at rs56007086 in MCF7 shows stronger FOXA1 binding to the alt A allele than to the ref G allele.; FOXA1 depletion or CRISPRi reduces TOX3 expression or enhancer reporter activity preferentially from the alt A allele in MCF7 cells.; The FOXA1 ChIP peak at this locus is reproducible in MCF7 and maps to the rs56007086-containing sequence.

Falsified if: Allele-specific FOXA1 binding at rs56007086 shows no difference between G and A, or shows stronger binding to the ref G allele.; FOXA1 depletion does not change TOX3 expression or enhancer reporter activity in an rs56007086 genotype-dependent manner.; The FOXA1 ChIP peak does not require or map to the rs56007086 sequence, or is explained by a linked variant such as rs4784227.

### 3. C2_CTCF_ref_insulator_TOX3: Ref allele strengthens CTCF binding near the TOX3 locus (p = 0.05)

TF CTCF (stated coverage not_checked; registry own_model), ref allele binds more; element dELS EH38E3180851 / ENSR16_9QTBS; gene TOX3; cell type MCF7 breast cancer.

| Step | Claim | Status | Evidence |
| --- | --- | --- | --- |
| binding | The claim that CTCF binds the ref G allele more strongly than the alt A allele at rs56007086 is a hypothesis. E03 reports a CTCF z-score of 1.9 for a nearby dELS 38 bp away; this is not variant-level, not allele-specific, and not MCF7-specific. CTCF QBiC-SELEX coverage is not_checked. | missing | [E03](#e03) |
| element | The variant is near dELS EH38E3180851 and within ENSR16_9QTBS, so altered CTCF binding could in principle affect insulator or enhancer activity. However, no cCRE overlaps the variant and the chromatin marks are biosample maxima, not MCF7-resolved. | supported | [E01](#e01), [E03](#e03) |
| gene | TOX3 is 17.6 kb upstream and CASC16 overlaps the variant, so a CTCF-dependent chromatin change could affect TOX3. This is proximity only; no chromatin-conformation, eQTL or perturbation evidence ties this element to TOX3, and E08 shows no breast-tissue eQTL for the variant. | weak | [E01](#e01), [E02](#e02), [E08](#e08) |
| cell_type | MCF7 is the supplied expression context, but the supplied evidence does not show CTCF occupancy or insulator activity at this locus in MCF7. | missing | none |
| phenotype | TOX3 is a breast cancer candidate locus and rs4784227 is a known TOX3 enhancer variant, but rs56007086 has no GWAS, Open Targets or variant-specific literature record. The disease link is therefore indirect and gene-level. | weak | [E06a](#e06a), [E06b](#e06b), [E04](#e04), [E05](#e05), [E09](#e09) |

Predictions: An allele-specific CTCF assay at rs56007086 shows stronger CTCF binding to the ref G allele than to the alt A allele.; CTCF depletion changes local chromatin conformation or TOX3 expression in an rs56007086 genotype-dependent manner in MCF7 cells.; The nearby CTCF signal maps to the rs56007086-containing sequence rather than only to the adjacent dELS.

Falsified if: No allele-specific CTCF binding is detected at rs56007086.; CTCF depletion does not affect chromatin conformation or TOX3 expression at this locus.; The CTCF signal maps to a different element and is not influenced by rs56007086.

### 4. C3_ESR1_alt_enhancer_TOX3: Alt allele strengthens ESR1 binding at a TOX3 enhancer (p = 0.05)

TF ESR1 (stated coverage not_checked; registry own_model), alt allele binds more; element ENSR16_9QTBS / nearby dELS EH38E3180851; gene TOX3; cell type MCF7 breast cancer.

| Step | Claim | Status | Evidence |
| --- | --- | --- | --- |
| binding | The claim that ESR1 binds the alt A allele more strongly than the ref G allele at rs56007086 is a hypothesis. No QBiC-SELEX, motif, ChIP-seq or allele-specific assay for ESR1 at this variant is supplied. ESR1 QBiC-SELEX coverage is not_checked. | missing | none |
| element | The variant is annotated within ENSR16_9QTBS and lies 38 bp from dELS EH38E3180851, which carries enhancer chromatin marks. No cCRE overlaps the variant and the marks are not MCF7-specific, so this is candidate-level element evidence. | supported | [E01](#e01), [E03](#e03) |
| gene | TOX3 is the nearest protein-coding gene at 17.6 kb upstream and CASC16 overlaps the variant. This is proximity only; there is no breast-tissue eQTL for rs56007086 in GTEx v8 and no contact or perturbation evidence linking this element to TOX3. | weak | [E01](#e01), [E02](#e02), [E08](#e08) |
| cell_type | MCF7 is the supplied breast cancer expression context, but the supplied evidence does not show ESR1 binding or estrogen responsiveness at this locus in MCF7. | missing | none |
| phenotype | ESR1 and TOX3 are both breast cancer candidate loci in a panel/imputation reanalysis, but neither that evidence nor any other supplied evidence mentions rs56007086, ESR1 binding at 16q12, or an estrogen-dependent TOX3 mechanism. The link is indirect and gene-level. | weak | [E06b](#e06b), [E04](#e04), [E05](#e05), [E09](#e09) |

Predictions: An allele-specific ESR1 assay at rs56007086 in MCF7 shows stronger ESR1 binding to the alt A allele than to the ref G allele.; Estrogen treatment or ESR1 depletion changes TOX3 expression or enhancer reporter activity in an rs56007086 genotype-dependent manner.; The alt-allele reporter is more responsive to ESR1 than the ref-allele reporter in ER-positive breast cancer cells.

Falsified if: ESR1 does not bind allele-specifically at rs56007086.; ESR1 depletion or estrogen treatment does not change TOX3 expression from this element.; The variant has no enhancer activity in estrogen-receptor-positive breast cancer cells.

## Prediction matrix

| Test | Cost | Separates top two | C4_null_no_TF_effect_linked_or_passenger | C1_FOXA1_alt_enhancer_TOX3 | C2_CTCF_ref_insulator_TOX3 | C3_ESR1_alt_enhancer_TOX3 |
| --- | --- | --- | --- | --- | --- | --- |
| Allele-specific FOXA1 binding at rs56007086 in MCF7 (ChIP-qPCR or EMSA with G vs A probes) | low | yes | No allele-specific FOXA1 binding difference; FOXA1 may occupy the region without allele specificity. | Alt A shows stronger FOXA1 binding than ref G. | No allele-specific FOXA1 binding; CTCF, if tested, may show ref preference. | No allele-specific FOXA1 binding; ESR1 may show alt preference if tested. |
| FOXA1 depletion or CRISPRi followed by TOX3 expression or enhancer reporter assay in MCF7 | medium | yes | No rs56007086 genotype-dependent effect on TOX3 or reporter activity. | FOXA1 loss reduces TOX3 or reporter activity preferentially for the alt A allele. | FOXA1 loss has no genotype-dependent effect on TOX3 or reporter activity. | FOXA1 loss has no genotype-dependent effect; ESR1 manipulation, not FOXA1, matters. |
| Allele-specific CTCF binding at rs56007086 | low | no | No allele-specific CTCF binding at the variant. | No allele-specific CTCF binding at the variant. | Ref G shows stronger CTCF binding than alt A. | No allele-specific CTCF binding at the variant. |
| Allele-specific ESR1 binding or estrogen-response reporter assay at rs56007086 in MCF7 | medium | no | No ESR1 allele-specific binding or genotype-dependent estrogen response. | No ESR1 allele-specific binding; FOXA1-dependent effect remains the candidate. | No ESR1 allele-specific binding; CTCF-dependent effect remains the candidate. | Alt A shows stronger ESR1 binding or stronger estrogen response than ref G. |
| CRISPR edit rs56007086 G>A in a breast cell line and measure TOX3 expression and chromatin contact | high | yes | No change in TOX3 expression or chromatin contact after editing rs56007086 alone. | Alt A increases FOXA1 occupancy and TOX3 expression or contact. | Ref G changes CTCF occupancy and chromatin conformation; TOX3 effect may be opposite or insulator-mediated. | Alt A increases ESR1 occupancy and estrogen-dependent TOX3 expression. |

## Next experiment

Cheapest separating experiment: allele-specific FOXA1 binding at rs56007086 in MCF7, using FOXA1 ChIP-qPCR on heterozygous MCF7 DNA or an EMSA with ref G and alt A probes. C1 predicts stronger FOXA1 binding to alt A; C4 predicts no allele-specific FOXA1 binding difference.

## Investigate calls

- chip_peaks({"tf": "FOXA1", "biosample": "MCF7"})
- eqtl_lookup({"tissue": "Breast - Mammary Tissue"})
- literature_search({"query": "rs56007086"})

## Flags

- literature_fallback: no hits for 'rs56007086 AND TOX3 AND "breast cancer"'; dropped the rsID

Citation support: 0.80 of links cite only evidence that passed every check.

## Evidence

<a id="e01"></a>**E01** variant_annotation, Ensembl VEP (GRCh38) (https://rest.ensembl.org/vep/human/region/16:52565398-52565398:1/A?content-type=application/json&Conservation=1; retrieved 2026-10-26T02:25:34+00:00)

> Variant chr16:52565398:G>A (GRCh38), allele string G/A
> Known IDs: rs56007086
> Most severe consequence: intron_variant
> Regulatory features: ENSR16_9QTBS enhancer
> GERP conservation score at the site: -4.73
> Transcript consequences: CASC16 (intron_variant, non_coding_transcript_variant)

<a id="e02"></a>**E02** nearest_genes, Ensembl overlap (protein_coding) (https://rest.ensembl.org/overlap/region/human/16:51565398-53565398?feature=gene;biotype=protein_coding;content-type=application/json; retrieved 2026-10-26T02:25:46+00:00)

> 6 protein-coding genes within 1000 kb of chr16:52565398:G>A, by distance to TSS:
> TOX3: 17.6 kb from TSS (upstream, strand -1)
> CHD9NB: 487.5 kb from TSS (downstream, strand -1)
> CHD9: 489.6 kb from TSS (upstream, strand +1)
> RBL2: 868.6 kb from TSS (upstream, strand +1)
> AKTIP: 939.0 kb from TSS (downstream, strand -1)
> HNRNPA1L3: 1012.0 kb from TSS (downstream, strand +1)

<a id="e03"></a>**E03** ccre_lookup, ENCODE v4 cCRE registry (ENCFF420VPZ) and SCREEN (https://screen-beta-api.wenglab.org/dataws/cre_table; retrieved 2026-10-26T02:25:06+00:00)

> No cCRE overlaps the variant; nearest is EH38E3180851 (dELS) 38 bp away.
> SCREEN: 1 cCREs within 500 bp (max z-score across ENCODE biosamples):
> EH38E3180851 dELS: DNase z 4.2, H3K27ac z 6.1, H3K4me3 z 1.8, CTCF z 1.9; nearby genes CASC16, TOX3, AC026462.5
> Biosample-specific z-scores are not in this call; the values above are maxima over biosamples.

<a id="e04"></a>**E04** gwas_lookup, GWAS Catalog REST v2 (https://www.ebi.ac.uk/gwas/rest/api/v2/associations?rs_id=rs56007086&size=100; retrieved 2026-10-26T02:25:35+00:00)

> 0 GWAS Catalog associations for rs56007086, strongest first:

<a id="e05"></a>**E05** finemap_lookup, Open Targets Platform (https://api.platform.opentargets.org/api/v4/graphql; retrieved 2026-10-26T02:25:34+00:00)

> Open Targets has no record of 16_52565398_G_A.

<a id="e06"></a>**E06** literature_search, Europe PMC REST (https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=TOX3%20AND%20%22breast%20cancer%22&format=json&pageSize=8&resultType=core; retrieved 2026-10-26T02:25:47+00:00)

> Europe PMC: 586 hits for 'TOX3 AND "breast cancer"'; top 7 with PMIDs:
> PMID 41230718 (2026): Cis-regulatory and long noncoding RNA alterations in breast cancer - current insights, biomarker utility, and the critical need for functional validation.
> PMID 41849381 (2026): A transcription regulator atlas identifies TOX3 as an Atoh1 coactivator in cerebellar development and tumorigenesis.
> PMID 41595182 (2026): Identification and Characterisation of Canine Osteosarcoma Biomarkers and Therapeutic Targets.
> PMID 41596432 (2026): Bone Metastasis in Estrogen Receptor-Positive Breast Cancer: Molecular Insights and Therapeutic Advances.
> PMID 40932605 (2025): Molecular signatures of breast cancer in the Iranian population: a review of cell growth and cell cycle regulators.
> PMID 42700350 (2026): Interactions between circular RNAs (circRNAs) and the Hippo pathway in cancer.
> PMID 41871294 (2026): A reanalysis of a genome-wide association study on breast cancer in Asian populations using the SG10K_Health reference panel for imputation: a multi-Centre case-control analysis.

<a id="e06a"></a>**E06a** literature_search, Europe PMC abstract, PMID 41230718 (https://europepmc.org/article/MED/41230718; retrieved 2026-10-26T02:25:47+00:00)

> Key examples include promoter mutations [e.g., rs2279744 (Mouse double minute 2 homolog gene; MDM2)], enhancer mutations [e.g., rs4784227 (thymocyte selection-associated high mobility group box family member 3 gene; TOX3)], and lncRNAs [e.g., HOX transcript antisense intergenic RNA (HOTAIR)] linked to progression, metastasis, and poor survival.

<a id="e06b"></a>**E06b** literature_search, Europe PMC abstract, PMID 41871294 (https://europepmc.org/article/MED/41871294; retrieved 2026-10-26T02:25:47+00:00)

> Differences in panel performance influenced association signals, including breast cancer candidate loci such as FGFR2, TOX3, and ESR1.

<a id="e07"></a>**E07** chip_peaks, Factorbook (ENCODE TF ChIP-seq peaks) (https://factorbook.api.wenglab.org/graphql; retrieved 2026-10-26T02:27:56+00:00)

> 1 ENCODE FOXA1 ChIP-seq peaks contain chr16:52565398:G>A in biosamples matching 'MCF7': biosamples MCF-7; experiments ENCSR126YEB. In other biosamples, 4 FOXA1 peaks do contain the variant: A549, HepG2, liver (experiments ENCSR000BMO, ENCSR000BRD, ENCSR735KEY).

<a id="e08"></a>**E08** eqtl_lookup, GTEx Portal API v2 (gtex_v8) (https://gtexportal.org/api/v2/association/singleTissueEqtl?variantId=chr16_52565398_G_A_b38&datasetId=gtex_v8; retrieved 2026-10-26T02:27:56+00:00)

> 0 significant GTEx v8 single-tissue eQTLs for chr16_52565398_G_A_b38 in tissues matching 'Breast - Mammary Tissue'. NES is the effect of the alt allele (A) relative to ref (G).

<a id="e09"></a>**E09** literature_search, Europe PMC REST (https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=rs56007086&format=json&pageSize=8&resultType=core; retrieved 2026-10-26T02:27:56+00:00)

> Europe PMC: 0 hits for 'rs56007086'; top 0 with PMIDs:
